Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Equivalents (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash & Equivalents for 16 consecutive years, with $57.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 3.33% to $57.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.5 million through Dec 2025, up 3.33% year-over-year, with the annual reading at $57.5 million for FY2025, 3.33% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $57.5 million at Anika Therapeutics, down from $58.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $97.2 million in Q2 2021, with the low at $53.2 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $74.4 million, with a median of $69.7 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 43.7% in 2021, then fell 28.8% in 2023.
  • Over 5 years, Cash & Equivalents stood at $94.4 million in 2021, then decreased by 8.54% to $86.3 million in 2022, then fell by 20.37% to $68.7 million in 2023, then fell by 19.07% to $55.6 million in 2024, then grew by 3.33% to $57.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $57.5 million, $58.0 million, and $53.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.